What Are the Symptoms of Reglan-Related Tardive Dyskinesia in Illinois?
Latest update (2025-07)
- FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]
What is the statute of limitations for Reglan tardive dyskinesia lawsuits in Illinois
In Illinois, the statute of limitations for Reglan (metoclopramide) tardive dyskinesia claims generally requires filing within two years from when the injury was discovered or should have been discovered. This is based on the FDA boxed warning about the risk of tardive dyskinesia with long-term use. Consult a qualified attorney for your specific case.
From General Health Education to Occupational Risk Awareness
If you or someone you know has taken Reglan and noticed unusual, involuntary movements, you may be experiencing tardive dyskinesia. Decades of medical research have established a clear link between this medication and movement disorders, underscoring the importance of early recognition. This page explains the specific symptoms to track and what they mean for your health.
Medical Evidence: Reglan and Tardive Dyskinesia Risk
Reglan (metoclopramide) is a medication approved for short-term treatment of symptomatic gastroesophageal reflux in adults and for relief of symptoms in adults with acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, its use carries a significant risk of tardive dyskinesia (TD), a potentially irreversible movement disorder. The FDA-approved labeling includes a boxed warning stating that metoclopramide, including Reglan, can cause TD, and that the risk increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD, and the labeling instructs healthcare providers to use the drug for the shortest duration necessary and to periodically reassess the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with symptomatic gastroesophageal reflux, the maximum duration of Reglan treatment is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In patients with diabetic gastroparesis, the labeling advises avoiding total treatment duration longer than 12 weeks, and if longer-term use is unavoidable, to routinely monitor for signs and symptoms of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Tardive dyskinesia is characterized by involuntary, repetitive movements of the face, tongue, trunk, and extremities. The labeling notes that metoclopramide can cause a syndrome of potentially irreversible and disfiguring involuntary movements, and that the drug may suppress or partially suppress the signs of TD, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The mechanistic pathway linking Reglan to TD involves chronic dopamine receptor blockade in the basal ganglia, leading to upregulation of dopamine receptors and subsequent hypersensitivity, which manifests as abnormal involuntary movements. This process is dose- and duration-dependent, with higher cumulative exposure increasing risk. From a risk perspective, the adequacy of warnings regarding Reglan and TD is a central issue. The boxed warning explicitly states the risk, but questions may arise about whether prescribers and patients were adequately informed about the potential for TD with long-term use, especially given that Reglan is often prescribed for conditions like diabetic gastroparesis where longer-term use may be considered. The labeling recommends immediate discontinuation of Reglan if signs or symptoms of TD develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, because TD can be irreversible, early detection and cessation of the drug are critical.
Statute of Limitations for Reglan Claims in Illinois
For affected patients in Illinois, settlement-related considerations involve the statute of limitations for filing a claim. In Illinois, personal injury claims generally must be filed within two years of the date the injury was discovered or should have been discovered. For TD, this timeline can be complex because symptoms may develop gradually and may not be immediately recognized as related to Reglan use. The latency period between exposure to Reglan and the onset of TD can vary, ranging from months to years, and the condition may be misdiagnosed initially. The statute of limitations clock typically starts when the patient knew or reasonably should have known that the injury was caused by the drug. Given that TD can be masked by continued use of metoclopramide, as noted in the labeling, the point of discovery may be delayed until after the drug is discontinued and symptoms become apparent. Settlement considerations also include the strength of evidence linking the patient's TD to Reglan use, the duration and dosage of Reglan therapy, and whether the prescribing physician followed recommended guidelines for short-term use. Patients who used Reglan for longer than 12 weeks without adequate monitoring may have stronger claims. Additionally, the presence of other risk factors, such as concomitant use of other drugs known to cause TD, should be evaluated. The labeling warns against concomitant use of other drugs known to cause TD, extrapyramidal symptoms, or neuroleptic malignant syndrome (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In summary, the medical narrative underscores that Reglan carries a known risk of TD, which is dose- and duration-dependent, and that the drug should be used for the shortest time necessary. For Illinois patients, the statute of limitations for filing a claim related to Reglan-induced TD is generally two years from discovery of the injury. Given the potential for delayed recognition of TD, affected individuals should seek legal counsel promptly to assess their specific circumstances and ensure compliance with applicable deadlines.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the statute of limitations for Reglan-induced tardive dyskinesia claims in Illinois?
In Illinois, personal injury claims generally must be filed within two years of the date the injury was discovered or should have been discovered. For tardive dyskinesia caused by Reglan, this timeline can be complex because symptoms may develop gradually and may not be immediately recognized as related to the drug. The clock typically starts when the patient knew or reasonably should have known that the injury was caused by Reglan. Given that TD can be masked by continued use of metoclopramide, the point of discovery may be delayed until after the drug is discontinued and symptoms become apparent. It is crucial to consult with an attorney promptly to assess your specific situation.
How does Reglan cause tardive dyskinesia?
Reglan (metoclopramide) can cause tardive dyskinesia through chronic dopamine receptor blockade in the basal ganglia, leading to upregulation of dopamine receptors and subsequent hypersensitivity, which manifests as abnormal involuntary movements. This risk is dose- and duration-dependent, with higher cumulative exposure increasing the likelihood of developing TD. The FDA-approved labeling includes a boxed warning about this risk and recommends using the drug for the shortest duration necessary (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
What are the symptoms of tardive dyskinesia?
Tardive dyskinesia is characterized by involuntary, repetitive movements of the face, tongue, trunk, and extremities. These movements can be disfiguring and are potentially irreversible. The labeling for Reglan notes that the drug may suppress or partially suppress the signs of TD, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Early detection and cessation of the drug are critical to prevent progression.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Related Articles
References
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.